Precursor B-cell lymphoblastic lymphoma: A study of nine cases lacking blood and bone marrow involvement and review of the literature

Anirban Maitra, Robert W. McKenna, Arthur G. Weinberg, Nancy R. Schneider, Steven H. Kroft

Research output: Contribution to journalArticle

Abstract

We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. Of these, 64% were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74% of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.

Original languageEnglish (US)
Pages (from-to)868-875
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume115
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
DNA Nucleotidylexotransferase
CD20 Antigens
CD45 Antigens
Immunophenotyping
Skin
B-Lymphoid Precursor Cells
Cytogenetic Analysis
HLA-DR Antigens
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymph Nodes
Bone and Bones
Survival

Keywords

  • Acute lymphoblastic leukemia
  • Lymphoblastic lymphoma
  • Precursor B-cell lymphoma, Precursor B-cell ALL

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Precursor B-cell lymphoblastic lymphoma : A study of nine cases lacking blood and bone marrow involvement and review of the literature. / Maitra, Anirban; McKenna, Robert W.; Weinberg, Arthur G.; Schneider, Nancy R.; Kroft, Steven H.

In: American Journal of Clinical Pathology, Vol. 115, No. 6, 2001, p. 868-875.

Research output: Contribution to journalArticle

Maitra, Anirban ; McKenna, Robert W. ; Weinberg, Arthur G. ; Schneider, Nancy R. ; Kroft, Steven H. / Precursor B-cell lymphoblastic lymphoma : A study of nine cases lacking blood and bone marrow involvement and review of the literature. In: American Journal of Clinical Pathology. 2001 ; Vol. 115, No. 6. pp. 868-875.
@article{672ce1b1ff02454381b9e22da9456a67,
title = "Precursor B-cell lymphoblastic lymphoma: A study of nine cases lacking blood and bone marrow involvement and review of the literature",
abstract = "We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25{\%} marrow involvement. Of these, 64{\%} were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74{\%} of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.",
keywords = "Acute lymphoblastic leukemia, Lymphoblastic lymphoma, Precursor B-cell lymphoma, Precursor B-cell ALL",
author = "Anirban Maitra and McKenna, {Robert W.} and Weinberg, {Arthur G.} and Schneider, {Nancy R.} and Kroft, {Steven H.}",
year = "2001",
doi = "10.1309/Q5GV-3K00-WAC6-BBUB",
language = "English (US)",
volume = "115",
pages = "868--875",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Precursor B-cell lymphoblastic lymphoma

T2 - A study of nine cases lacking blood and bone marrow involvement and review of the literature

AU - Maitra, Anirban

AU - McKenna, Robert W.

AU - Weinberg, Arthur G.

AU - Schneider, Nancy R.

AU - Kroft, Steven H.

PY - 2001

Y1 - 2001

N2 - We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. Of these, 64% were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74% of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.

AB - We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. Of these, 64% were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74% of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.

KW - Acute lymphoblastic leukemia

KW - Lymphoblastic lymphoma

KW - Precursor B-cell lymphoma, Precursor B-cell ALL

UR - http://www.scopus.com/inward/record.url?scp=0035000322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035000322&partnerID=8YFLogxK

U2 - 10.1309/Q5GV-3K00-WAC6-BBUB

DO - 10.1309/Q5GV-3K00-WAC6-BBUB

M3 - Article

C2 - 11392884

AN - SCOPUS:0035000322

VL - 115

SP - 868

EP - 875

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -